Search PubMed⌕ Search

Biomedical subjects

K Ewe

Publications and source records attributed to K Ewe.

156 records · Page 9Linked to original sources
PubMedDate not supplied

Bacteremia after proctoscopy and hemorrhoidal injection sclerotherapy.

The incidence of bacteremia following proctoscopy and hemorrhoidal injection sclerotherapy was studied in 50 outpatients undergoing both procedures. Bacteremia was found in 2 per cent of the subjects after proctoscopy and in 8 per cent after sclerotherapy. None of the subjects developed symptoms of septicemia following the procedure. It is concluded that antibiotic prophylaxis should be used before sclerotherapy in patients with valvular heart disease or compromised host defense.

Adult↗
PubMedDate not supplied

[Spermatogram evaluation in cases with Crohn disease].

In 29 men with Morbus Crohn sperm density was less than 20 MIll/ml in 14 cases. There was a lack of motility of spermatozoa in 19 cases and 26 cases Spermmorphology was pathological. Although the LH-and Testosteron-levels were normal, we found decreased FSH-levels in six cases. Seminalplasmafluid was pathological in 10 cases. According to the guidelines of Eliasson for estimating semen qualities, 21 were severe pathological, 4 were pathological and 4 doubtful. We discussed the different etiological possibilities of Morbus Crohn and their possible influences on spermatogenesis.

Crohn Disease↗
PubMedDate not supplied

Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.

BACKGROUND/AIMS: Budesonide is a glucocorticoid with a high topical anti-inflammatory but low systemic activity due to its rapid hepatic inactivation. The aim of this open, multicenter study was to investigate efficacy and safety of oral pH-modified-release budesonide in patients with active Crohn's disease of the ileum and colon and in maintaining budesonide-induced remission in postactive Crohn's disease. MATERIALS AND METHODS: 81 patients (intention-to-treat) received 3 x 3 mg budesonide/day for 6 weeks, followed by 3 x 2 mg budesonide for another 6 weeks in case of response to initial treatment. Clinical and laboratory parameters were assessed at study entry as well as after 2, 4, 6 and 12 weeks of treatment. RESULTS: On an intention-to-treat basis remission was induced in 54.3% of 81 patients with active Crohn's disease, 71.4% of 35 patients stayed in remission after the acute-phase treatment until the end of the trial. Typical steroid-related side effects were observed during the acute-phase treatment in only 18% of the patients. Duration, severity and extent of disease at study entry played no significant role in the outcome of the trial, but there was a tendency towards better results during the acute-phase treatment in patients with moderate disease activity and affection of the terminal ileum and proximal colon. CONCLUSIONS: Budesonide could be an alternative to conventional steroid treatment in patients with active Crohn's disease.

Administration, Oral↗